SPOTLIGHT: Gardasil wins priority review

The FDA is giving a priority review to Merck's request to expand the use of Gardasil to protect against cervical cancer in women up to the age of 45. The vaccine is currently approved for girls aged 9 to 26. Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.